Biotronik, has used the annual European Society of Cardiology event at which to announce what it calls ground-breaking results from its IN-TIME study. This is the first randomized, controlled trial worldwide, and demonstrates a significant reduction in all-cause mortality in heart failure patients with implant-based remote monitoring.
Pacing and remote monitoring technology company Biotronik has announced the European market launch of its Ilesto 7 Series. Ilesto 7 … continue reading “EU Market Sees Launch Of World’s First MR Approved DF4 ICD/CRT-D System”
Heart device and monitoring company Biotronik, has completed enrollment for its the highly anticipated IMPACT study. The study aims to investigate whether the use of Biotronik Home Monitoring® in conjunction with anticoagulation can reduce the risks of stroke, systemic embolism and major bleeding in cardiac device patients
Cardiac device and remote monitoring specialist company Biotronik is 50 years old. The company is having a double celebration as it is also announcing the CE mark approval of its MRI compatible Iforia ICD/CRT-D implant
Biotronik has announced the FDA approval of its Lumax 740 DX System. This novel device is a first-in-class implantable cardiac defibrillator (ICD) that utilizes a single lead with atrial sensing capabilities.
Biotronik has announced that its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D) series has received CE approval. The device family includes the one of the world’s smallest ICDs and is MRI compatible as well as being equipped with Biotronik Home Monitoring® technology.
Findings from a newly published study suggest that as well as improving patient care, remote monitoring using Biotronik’s proprietary system also takes pressure of the clinical routine.
Cardiac device and remote monitoring company Biotronik, has gained U.S. FDA approval to commence its ProMRI® clinical trial under an Investigational Device Exemption (IDE). Recruitment is underway.
A new paper, published in the European Heart Journal shows home-monitored patients experience 71% fewer delivered shocks and a 52% reduction in inappropriate shocks compared with a control group.
More good news for Biotronik’s peripheral vascular business as its Pulsar 18 study gets underway in the U.S., hot on the heels of favourable clinical study results from Europe.
Clinical study results show strong evidence of benefits for lower limb intervention when using Pulsar stents, with no statistical difference between heavily calcified and non calcified lesions.
Biotronik has announced the launch of its 3Flow Aspiration Catheter which is designed to facilitate quick and accurate thrombus aspiration, and complements the company’s Coronary Vascular Intervention portfolio.
Biotronik has introduced its Pulsar stent technology in a 0.035″/6F platform, building on what it claims is the success of its Pulsar 18, 0.018″/4F version. It’s also trumpeting a new infrapopliteal PTA balloon called Passeo 14 which it claims offers a new level of utility with the promise of shortened procedure time.
The first patient has now been enrolled in the Biotronik-supported study which aims to identify risk factors that can help predict appropriateness of ICD interventions.
A unique algorithm in Biotronik’s Lumax 740 ICD differentiates atrial from ventricular arrhythmias to avoid risk for potential long-term medical consequences of painful and inappropriate shocks.
Biotronik has announced that the first cardiac resynchronisation therapy device (CRT-D) patient has been enrolled in its so-called EuroEco Trial—the European Health Economic Trial on Home Monitoring in implantable cardioverter-defibrillator (ICD) and CRT-D patients.